ReviewInternational journal of rheumatic diseases2021
Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic.
Review in International journal of rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Communication to promote and support physical distancing for COVID-19 prevention and control: a rapid reviewThe Cochrane database of systematic reviews · 2023Pooled it
- A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.Dermatologic therapy · 2022Pooled it
- COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases.Vaccines · 2023Review
- COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs.RMD open · 2023Article
- COVID-19 Vaccination and the Development of Autoimmune Diseases.Internal medicine (Tokyo, Japan) · 2023Article
- Learning from the COVID-19 pandemic: health care disturbances and telemedicine as an alternative rheumatology practice in Indonesia.BMC health services research · 2023Article
- A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia.Inflammation and regeneration · 2023Review
- Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.Frontiers in pharmacology · 2023Review
- The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases.Journal of clinical medicine · 2022Article
- Covid-19 vaccination in autoimmune rheumatic diseases: A multi-center survey from southern India.International journal of rheumatic diseases · 2022Article
- Antibody responses to inactivated and mRNA SARS-CoV-2 vaccines in familial Mediterranean fever patients treated with interleukin-1 inhibitors.Rheumatology (Oxford, England) · 2022Article
- COVID-19 vaccination in patients with rheumatic diseases: Vaccination rates, patient perspectives, and side effects.Immunity, inflammation and disease · 2022Article
- Evaluation of the use of video consultation in German rheumatology care before and during the COVID-19 pandemic.Frontiers in medicine · 2022Article
- One year of digital health applications (DiGA) in Germany - Rheumatologists' perspectives.Frontiers in medicine · 2022Article
- COVID-19 pneumonia can cause irreversible lung damage in dermatomyositis with pre-existing interstitial lung disease.International journal of rheumatic diseases · 2021Article
- Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic.International journal of rheumatic diseases · 2021Review
- Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 19 institutions in 12 countries.
Funding
Abstract
aimTo update previous guidance of the Asia Pacific League of Associations for Rheumatology (APLAR) on the management of patients with rheumatic and musculoskeletal diseases (RMD) during the coronavirus disease 2019 (COVID-19) pandemic.
methodsResearch questions were formulated focusing on diagnosis and treatment of adult patients with RMD within the context of the pandemic, including the management of RMD in patients who developed COVID-19. MEDLINE was searched for eligible studies to address the questions, and the APLAR COVID-19 task force convened 2 meetings through video conferencing to discuss its findings and integrate best available evidence with expert opinion. Consensus statements were finalized using the modified Delphi process.
resultsAgreement was obtained around key aspects of screening for or diagnosis of COVID-19; management of patients with RMD without confirmed COVID-19; and management of patients with RMD with confirmed COVID-19. The task force achieved consensus on 25 statements covering the potential risk of acquiring COVID-19 in RMD patients, advice on RMD medication adjustment and continuation, the roles of telemedicine and vaccination, and the impact of the pandemic on quality of life and on treatment adherence.
conclusionsAvailable evidence primarily from descriptive research supported new recommendations for aspects of RMD care not covered in the previous document, particularly with regard to risk factors for complicated COVID-19 in RMD patients, modifications to RMD treatment regimens in the context of the pandemic, and COVID-19 vaccination in patients with RMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.